1
|
Smith BD, Fichthorn KA, Kirby DJ, Quimby LM, Triplett DA, González P, Hernández D, Keating CD. Asymmetric van der Waals forces drive orientation of compositionally anisotropic nanocylinders within smectic arrays: experiment and simulation. ACS Nano 2014; 8:657-70. [PMID: 24308771 PMCID: PMC3926316 DOI: 10.1021/nn405312x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Understanding how micro- and nanoparticles interact is important for achieving bottom-up assembly of desired structures. Here, we examine the self-assembly of two-component, compositionally asymmetric nanocylinders that sediment from solution onto a solid surface. These particles spontaneously formed smectic arrays. Within the rows of an array, nanocylinders tended to assemble such that neighboring particles had the same orientation of their segments. As a probe of interparticle interactions, we classified nanocylinder alignments by measuring the segment orientations of many sets of neighboring particles. Monte Carlo simulations incorporating an exact expression for the van der Waals (vdW) energy indicate that differences in the vdW interactions, even when small, are the key factor in producing observed segment alignment. These results point to asymmetrical vdW interactions as a potentially powerful means of controlling orientation in multicomponent cylinder arrays, and suggest that designing for these interactions could yield new ways to control self-assembly.
Collapse
Affiliation(s)
- Benjamin D. Smith
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Kristen A. Fichthorn
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802
- Department of Physics, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - David J. Kirby
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Lisa M. Quimby
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Derek A. Triplett
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Pedro González
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Darimar Hernández
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| | - Christine D. Keating
- Department of Chemistry, The Pennsylvania State University, University Park, Pennsylvania 16802
| |
Collapse
|
2
|
Abstract
We use Monte Carlo simulations in two dimensions to study the depletion forces between two hard squares in a suspension of hard rods or disks. We determine the effects of size and concentration of rods and disks on the potential of mean force between the squares. Both rods and disks produce a short-range depletion attraction between the two squares. The depletion interaction can be strong enough to outweigh the (rotational) entropic repulsion between the squares at certain sizes and concentrations of the rods and disks. We also probe the relative orientation that two squares adopt as they approach each other and we observe rich behavior, in which the relative orientation depends on the size, concentration, and shape of the depletion agent. Simple models based on the ideas of Asakura and Oosawa [J. Chem. Phys. 22, 1255 (1954)] can explain trends in the potentials of mean force obtained from the simulations.
Collapse
Affiliation(s)
- Derek A Triplett
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | | |
Collapse
|
3
|
Triplett DA, Quimby LM, Smith BD, Rodríguez DH, St. Angelo SK, González P, Keating CD, Fichthorn KA. Assembly of gold nanowires by sedimentation from suspension: Experiments and simulation. J Phys Chem C Nanomater Interfaces 2010; 114:7346-7355. [PMID: 20544001 PMCID: PMC2882699 DOI: 10.1021/jp909251v] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
We investigated the ordering of gold nanowires that settled from aqueous suspension onto a glass substrate due to gravity. The nanowires, ca. 300 nm in cross-sectional diameter and ca. 2, 4, or 7 microns in length, were coated with 2-mercaptoethanesulfonic acid to provide electrostatic repulsion and prevent aggregation. The layer of nanowires in direct contact with the substrate was examined from below using optical microscopy and found to exhibit smectic-like ordering. The extent of smectic ordering depended on nanowire length with the shortest (2 μm) nanowires exhibiting the best ordering. To understand the assembly in this system, we used canonical Monte Carlo simulations to model the two-dimensional ordering of the nanowires on a substrate. We accounted for van der Waals and electrostatic interactions between the nanowires. The simulations reproduced the experimental trends and showed that roughness at the ends of the nanowires, which locally increased electrostatic repulsion, is critical to correctly predicting the experimentally observed smectic ordering.
Collapse
|
4
|
Triplett DA, Kocoshis TA, Harms CS. Factor assay (VIII and IX) results in the College of American Pathologists Survey Program (1976-1979). Scand J Haematol Suppl 2009; 37:116-29. [PMID: 6787698 DOI: 10.1111/j.1600-0609.1980.tb01348.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Data from the 1976-1979 CAP Surveys for Factor VIII assays are reviewed. Beginning in 1979, Factor IX assays were also performed by survey participants. Data was obtained from approximately 2500 laboratories and the different instrument-reagents are ranked according to precision and sensitivity. Also, the results of questionnaires on specific assay techniques (1977 through 1979) are analyzed. A trend was noted indicating an increasing number of laboratories are now performing factor assays. There is poor correlation between precision and sensitivity of most systems (i.e., instrument and reagent combination). For any given system, there was considerable variation in precision from a normal Factor VIII levels specimen to a low Factor VIII specimen. This was also the case with respect to Factor IX assays. With respect to the technical aspects of factor assays there was marked interlaboratory variation (i.e., dilution of normal plasma used to construct standard curve, etc.). The need for standardization of factor assays is evident from the survey data.
Collapse
|
5
|
Triplett DA. The College of American Pathologists (CAP) Survey Program. Scand J Haematol Suppl 2009; 37:156-7. [PMID: 6941436 DOI: 10.1111/j.1600-0609.1980.tb01354.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
6
|
Maas RL, Triplett DA, Tholen D. Factor VIII assay proficiency assessment: experience in the USA. Scand J Haematol Suppl 2009; 41:109-20. [PMID: 6440277 DOI: 10.1111/j.1600-0609.1984.tb02772.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
7
|
Triplett DA, Fichthorn KA. Monte Carlo simulation of two-dimensional hard rectangles: confinement effects. Phys Rev E Stat Nonlin Soft Matter Phys 2008; 77:011707. [PMID: 18351866 DOI: 10.1103/physreve.77.011707] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/03/2007] [Revised: 09/24/2007] [Indexed: 05/26/2023]
Abstract
We use orientational-bias Monte Carlo simulations to examine the phase behavior of two-dimensional hard rectangles in the bulk and under confinement by hard walls. For all of the rod aspect ratios and area fractions studied, we find that confinement increases the degree of nematic ordering over the bulk, as confined rods tend to align their long axes parallel to the confining walls. The extent of nematic ordering increases as the separation between the confining walls decreases. If the aspect ratio of the rectangles is sufficiently large, they exhibit nematic ordering in both the bulk and under confinement, where the nematic director is set by the walls. Rods with a small aspect ratio are isotropic in the bulk and exhibit weak tetratic tendencies for sufficiently high densities. From studies of density profiles, angular distributions, and orientational correlation functions for confined, low-aspect-ratio rods, it is apparent that they align their long axes parallel to the wall in the near-wall region, where layering occurs for sufficiently high rod densities. However, confined rods with low aspect ratios still exhibit weak tetratic (isotropic) tendencies near the center of the confined region for all but the smallest wall separations. We note that although our studies probe the ordering of hard rectangles, the entropic tendencies that we observe here will be present for rods with energetic interactions. Thus, these studies serve as a general starting point for understanding and controlling the assembly of rods in two-dimensional confining geometries.
Collapse
Affiliation(s)
- Derek A Triplett
- Department of Chemical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | | |
Collapse
|
8
|
Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, Ramos-Casals M, Martínez-González AL, Ingelmo M, Reverter JC, Font J, Triplett DA. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005; 64:943-6. [PMID: 15897312 PMCID: PMC1755506 DOI: 10.1136/ard.2004.026377] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Disseminated intravascular coagulation (DIC) is an acquired syndrome characterised by formation of microthrombi and fibrin deposition in the microvasculature. The catastrophic antiphospholipid syndrome (APS) is characterised by multiorgan thrombosis, mainly involving small vessels. A broad spectrum of disorders may develop DIC features; however, the catastrophic APS has not previously been recognised as a cause of DIC. OBJECTIVE To analyse the clinical and laboratory characteristics of catastrophic APS patients with DIC features. METHODS The web site based international registry of patients with catastrophic APS (CAPS registry) (http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) was analysed and the cases with DIC features selected. RESULTS In 173 patients with catastrophic APS, 23 (13%) were found with DIC features. The clinical and immunological characteristics were similar in catastrophic APS patients with and without DIC features; a significant difference was found only in the prevalence of thrombocytopenia (100% in patients with DIC features v 59% in those without DIC features). CONCLUSIONS DIC features are not rare in catastrophic APS, supporting the need for systematic screening of antiphospholipid antibodies in all patients with DIC features without precipitating factors. The presence of DIC features in the context of an APS makes it imperative to rule out the catastrophic variant of this syndrome.
Collapse
Affiliation(s)
- R A Asherson
- Servei de Malalties Autoimmunes, Hospital Clínic, Villarroel 170, 08036-Barcelona, Catalonia, Spain
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Brennan SO, Wyatt JM, Fellowes AP, Dlott JS, Triplett DA, George PM. Gamma371 Thr-->Ile substitution in the fibrinogen gammaD domain causes hypofibrinogenaemia. Biochim Biophys Acta 2001; 1550:183-8. [PMID: 11755207 DOI: 10.1016/s0167-4838(01)00280-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Six members of a family with hypofibrinogenaemia had fibrinogen concentrations ranging from 0.5 to 1.1 mg/ml and, after sequencing the entire coding region and the intron exon boundaries of all three fibrinogen genes, a single heterozygous ACT-->ATT mutation was identified in the gamma gene. This novel mutation was not detected in normal family members or unrelated controls. The gamma371 Thr-->Ile substitution occurs at a conserved threonine in the gammaD domain, but molecules containing the new isoleucine were not present in circulating fibrinogen. The evidence for this was that purified gamma chains had a normal mass of 48375 Da compared to a control of 48374 Da, and tryptic peptide maps were entirely normal. The mutation predicts a mass increase of 12 Da in peptide T-36, but on mass mapping only the normal [M+2H] ion was detected, at 948 m/z. There was no new signal at 954 m/z that would indicate expression of variant chains. Also the normal 948 m/z signal was at the same intensity in digests from the proposita and controls. Crystal structures show a hydrogen bond from the threonine hydroxyl to the main chain and this case suggests this bond is critical in maintaining the structure of the gammaD domain.
Collapse
Affiliation(s)
- S O Brennan
- Molecular Pathology Laboratory, Canterbury Health Laboratories, P.O. Box 151, Christchurch, New Zealand.
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
Although there is international consensus regarding the general principles of testing for lupus anticoagulants (LAs), no agreement exists as far as the analysis of the clotting time results is concerned. Twenty-nine laboratories participating in the Fifth International Survey of Lupus Anticoagulants (ISLA-5) reported the activated partial thromboplastin time (APTT)-based clotting times obtained on seven defined test samples and a normal plasma (NP) using the same two reagents with low and high phospholipid (PL) concentrations, respectively. These clotting times were used to analyse how various methods of calculating the results may influence the apparent sensitivity of LA tests. We found that the use of a separate screening test may lead to the exclusion of samples where the presence of LA would have been detected by a combined screening and confirmatory method. For instance, the dilute APTT (dAPTT) gave a sensitivity of 53.5% (screening test), while the calculation of a ratio between the clotting times obtained with two different PL concentrations gave a sensitivity of 68.1% (confirmatory test). The normalisation of results by dividing with the corresponding results of NP increased the apparent sensitivity. The screening test ratio between dAPTT results of test samples and NP gave a sensitivity of 84.7%. The normalised ratio between the clotting times obtained with the two reagents (lupus ratio, LR) gave a sensitivity of 95.1%. We conclude that when testing for LA, all samples should be tested with both low (screening procedure) and high (confirmatory procedure) PL concentrations. These two clotting times should be evaluated in relation to each other and to the corresponding results obtained with a reference plasma (normalisation).
Collapse
Affiliation(s)
- E M Jacobsen
- Haematological Research Laboratory, Medical Clinic, Ullevål University Hospital, Oslo, Norway.
| | | | | | | | | |
Collapse
|
11
|
Zhao D, Ogawa H, Wang X, Cameron GS, Baty DE, Dlott JS, Triplett DA. Oxidized low-density lipoprotein and autoimmune antibodies in patients with antiphospholipid syndrome with a history of thrombosis. Am J Clin Pathol 2001; 116:760-7. [PMID: 11710695 DOI: 10.1309/1ryq-q2aj-ckf7-ycde] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The prevalence and clinical significance of plasma oxidized low-density lipoprotein (oxLDL) and antibodies against oxLDL (anti-oxLDL) were evaluated in patients with antiphospholipid syndrome (APS). OxLDL and IgG anti-oxLDL were determined by enzyme-linked immunosorbent assay in plasma samples from 80 patients with APS. Positive values (mean + 3 SD) for oxLDL and anti-oxLDL were found in 21 (26%) and 19 (24%) of 80 patients with APS, respectively These values were significantly higher than those in healthy subjects. Levels of oxLDL and anti-oxLDL antibodies in subgroupings of patients with APS who had experienced thrombotic events were compared. There were significant differences among the groups for the levels of both oxLDL and anti-oxLDL antibodies. Pairwise comparisons between the groups yielded similar but not identical results. There was a significant, positive correlation between levels of plasma oxLDL and anti-oxLDL. These results suggest that elevated levels of plasma oxLDL and anti-oxLDL may be risk factors and potential markers for thrombosis, especially for arterial thrombotic events, in patients with APS.
Collapse
Affiliation(s)
- D Zhao
- Department of Research, Ball Memorial Hospital, Munice, IN, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD. Beta2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of beta2-glycoprotein I. Thromb Haemost 2001; 86:590-5. [PMID: 11522008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Many of the autoantibodies in antiphospholipid syndrome (APS) are directed against beta2-glycoprotein I (beta2-GPI). Recent studies from our laboratories have indicated that the immunodominant binding epitope(s) for high titer, affinity purified antibodies from 11 APS patients are localized to the amino terminal domain (domain 1) of beta2-GPI. The present study employed surface plasmon resonance to localize the immunodominant domain in serum samples from a large cohort of patients with GPL values ranging from 21 to 230 units (n = 106 patients). Eighty-eight percent of patients showed > or = threefold selectivity for beta2-GPI containing domain 1 relative to the domain deletion mutant that lacked domain 1. The domain 1 binding activity in patient serum was abolished by removing the IgG fraction from the serum and the binding activity could be fully reconstituted with the IgG fraction. Thus, analysis of serum samples from a large cohort of APS patients indicates that the immunodominant binding epitope(s) for anti-beta2 antibodies are localized to the amino terminal domain of beta2-GPI.
Collapse
Affiliation(s)
- P A McNeeley
- La Jolla Pharmaceutical Company, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
The authors summarize the current knowledge in the area of novel risk factors for venous thrombosis, both genetic and acquired causes of hypercoagulability. Because the list of genetic defects that predispose carriers to develop thrombosis has increased significantly in recent years, along with the available assays to test for them, hypercoagulability has been a subject of much discussion. This review highlights the issues on hypercoagulability that pathologists who are not specialists in coagulation should be familiar with, in order to provide consultation to other physicians. An educated approach to the diagnosis of this newly described group of disorders will ensure more cost-effective and efficient care to patients at risk.
Collapse
Affiliation(s)
- M B Marques
- Department of Pathology, University of Alabama at Birmingham, AL 35233-7331, USA
| | | |
Collapse
|
14
|
Galli M, Dlott J, Norbis F, Ruggeri L, Cler L, Triplett DA, Barbui T. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost 2000; 84:1012-6. [PMID: 11154107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
The dilute Russell's viper venom time (dRVVT) and the kaolin clotting time (KCT) are two among the most commonly used coagulation tests for the detection of lupus anticoagulants. The dRVVT seems superior to the KCT in identifying LA-positive patients at risk of thrombosis. However, this relationship is greatly influenced by both the source of reagents and the instrumentation employed to carry out the assays. Therefore, 4 dRVVTs ("home-made" dRVVT, DVV test, Bioclot LA, LA Screen), and one KCT (Kaoclot) were performed in two centers and compared for their retrospective correlation with the thrombotic complications of 72 patients with a previously established diagnosis of lupus anticoagulants. Two other assays ("home-made" KCT, and Colloidal Silica Clotting Time, CSCT) were performed in one of the two centers, and compared with Kaoclot for their clinical correlations in the same population of patients, 44 of whom (61%) had suffered from arterial and/or venous thrombosis. A rather good degree of inter-laboratory and inter-assay correlations of the different tests was found. However, a statistically significant association with thrombosis was found only with the coagulation profile generated using the "home-made" dRVVT. When the commercially available dRVVTs were used, none of the coagulation profiles remained associated with thrombosis. When the assays were analyzed separately, the association with thrombosis was statistically significant for LA screen (p = 0.0019), DVV test (p = 0.0043), and Bioclot (p = 0.0255), and of borderline significance for the "home-made" dRVVT (p = 0.0503) in one center. This last assay was also significantly associated with thrombosis in the other center (p = 0.0139). When venous and arterial thrombosis were considered separately, DVV test was statistically associated with venous thrombosis in both centers (p = 0.0076 and p = 0.0187, respectively), and LA screen in one center (p = 0.0303). No dRVVT was found to correlate with arterial thrombosis. Kaoclot, Colloidal Silica Clotting Time, and the "home-made" KCT did not correlate with thrombosis. The prevalence of IgG and/or IgM antibodies to cardiolipin, beta2-glycoprotein I and prothrombin were 74%, 86% and 85%, respectively. Increased titers of IgG anticardiolipin antibodies were associated with arterial thrombosis (p = 0.0375), whereas IgM anti-beta2-glycoprotein I antibodies were associated with venous thrombosis (p = 0.0433). In conclusion, these retrospective data support the notion that the dRVVT, rather than other coagulation or ELISA tests, are able to identify lupus anticoagulant-positive patients at risk of thrombosis. This property appears common to several commercially available dRVVT kits, making this type of assay the ideal target of future efforts of laboratory standardization.
Collapse
Affiliation(s)
- M Galli
- Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
| | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
Antiphospholipid antibodies (APA) are a common cause of acquired thrombophilia. APA recognize plasma phospholipid-binding proteins (e. g., beta(2)-glycoprotein I, prothrombin, annexin V, etc.). Catastrophic antiphospholipid syndrome (CAPS) is an uncommon variant of the antiphospholipid syndrome. CAPS patients often present with multiorgan failure. Precipitating factors include surgical procedures, drugs, and discontinuation of anticoagulant therapy. Increasingly, infections are recognized as a major precipitating condition. The majority of patients present with renal involvement as well as evidence of acute respiratory distress syndrome (ARDS). This review discusses the clinical and pathophysiologic aspects of CAPS as well as the differenital diagnosis.
Collapse
Affiliation(s)
- D A Triplett
- Midwest Hemostasis and Thrombosis Laboratories, Ball Memorial Hospital, Muncie, Indiana 47303, USA.
| | | |
Collapse
|
16
|
Ogawa H, Zhao D, Dlott JS, Cameron GS, Yamazaki M, Hata T, Triplett DA. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 2000; 114:619-28. [PMID: 11026109 DOI: 10.1309/298h-nlbu-e47g-8pyl] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
To clarify the involvement of annexin V (ANX) in antiphospholipid antibody (APA) specificities, we studied antiANX antibodies (aANX) using 2 kinds of enzyme-linked immunosorbent assay plates (plain and gamma-irradiated) and anti-beta 2-glycoprotein I antibodies (a-beta 2GPI) in 53 patients with antiphospholipid syndrome (APS). The incidence of aANX IgG-positive results in the autoimmune APS group was significantly higher than that of healthy control subjects. However, we could not demonstrate a significantly higher incidence in the infection- or drug-induced group. Nor could we find an increased incidence of IgM isotype. When the 2 plates were compared, the discrepancies of positivity were demonstrated in both isotypes. We speculated that these discrepancies between the plate surfaces were attributed to the altered antigenicity of ANX. Although positivity of a-beta 2GPI was associated significantly with clinical manifestations, no significant associations were demonstrated between the incidence of aANX-positive results and clinical manifestations. We inferred that the involvement of aANX in the pathogenic mechanism of APS is unlikely.
Collapse
Affiliation(s)
- H Ogawa
- Department of Research, Ball Memorial Hospital, Muncie, IN, USA
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
Antiphospholipid antibodies (APA) are now recognized as the most common cause of acquired thrombophilia. These antibodies may lead to thrombosis in both arterial and venous sites. Lupus anticoagulants (LA) are the most significant risk factor among the various APAs. The detection of LAs remains challenging to most laboratories. Multiple screening tests are recommended (e.g. APTT, dilute PT and dRVVT). The dRVVT is one of the most important screening procedures. In many instances, commercially available dRVVT systems include a screening reagent with low PL concentration and a confirmatory product with high PL concentration. There are a number of commercially available dRVVT test systems. These reagents vary in phospholipid origin and concentration as well as source of Russell viper venom (RVV). It is imperative for laboratories to be well informed regarding reagent composition and laboratory performance.
Collapse
|
18
|
Matsuura E, Inagaki J, Kasahara H, Yamamoto D, Atsumi T, Kobayashi K, Kaihara K, Zhao D, Ichikawa K, Tsutsumi A, Yasuda T, Triplett DA, Koike T. Proteolytic cleavage of beta(2)-glycoprotein I: reduction of antigenicity and the structural relationship. Int Immunol 2000; 12:1183-92. [PMID: 10917893 DOI: 10.1093/intimm/12.8.1183] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Binding of beta(2)-glycoprotein I (beta(2)-GPI)-dependent anticardiolipin antibodies (aCL) derived from antiphospholipid syndrome (APS) is significantly reduced in aCL ELISA due to loss of the phospholipid (PL) binding property of beta(2)-GPI by plasmin treatment. In the present study, the treatment generated a nicked form of beta(2)-GPI and resulted in loss of antigenicity for the autoantibodies detected in ELISA, using an beta(2)-GPI directly adsorbed polyoxygenated carboxylated plate, the assay system of which was not related to PL binding. The nicked form bound to neither Cu(2+)-oxidized low-density lipoprotein (oxLDL) nor to beta(2)-GPI-specific lipid ligands isolated from oxLDL, the result being a complete loss of subsequent binding of anti-beta(2)-GPI autoantibodies. The conformational change in the nicked domain V was predicted from its intact structure determined by an X-ray analysis (implemented in Protein Data Bank: 1C1Z), molecular modeling and epitope mapping of a monoclonal anti-beta(2)-GPI antibody, i.e. Cof-18, which recognizes the related structure. The analysis revealed that novel hydrophobic and electrostatic interactions appeared in domain V after the cleavage, thereby affecting the PL binding of beta(2)-GPI. Such a conformational change may have important implications for exposure of cryptic epitopes located in the domains such as domain IV.
Collapse
Affiliation(s)
- E Matsuura
- Department of Cell Chemistry, Institute of Cellular and Molecular Biology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Triplett DA. Coagulation and bleeding disorders: review and update. Clin Chem 2000; 46:1260-9. [PMID: 10926920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Hemostasis is initiated by injury to the vascular wall, leading to the deposition of platelets adhering to components of the subendothelium. Platelet adhesion requires the presence of von Willebrand factor and platelet receptors (IIb/IIIa and Ib/IX). Additional platelets are recruited to the site of injury by release of platelet granular contents, including ADP. The "platelet plug" is stabilized by interaction with fibrinogen. In this review, I consider laboratory tests used to evaluate coagulation, including prothrombin time, activated partial thromboplastin time, thrombin time, and platelet count. I discuss hereditary disorders of platelets and/or coagulation proteins that lead to clinical bleeding as well as acquired disorders, including disseminated intravascular coagulation and acquired circulating anticoagulants.
Collapse
Affiliation(s)
- D A Triplett
- Indiana University School of Medicine and Midwest Hemostasis and Thrombosis Laboratories, Ball Memorial Hospital, Muncie, IN 47303,
| |
Collapse
|
20
|
Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisløff F. The Lupus Ratio test--an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants--ISLA 5. Thromb Haemost 2000; 83:704-8. [PMID: 10823266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The Lupus Ratio (LR) test for lupus anticoagulants integrates screening, mixing with normal plasma and confirmation procedures into one assay. The sensitivity and reproducibility of the APTT based version of this assay was tested in an interlaboratory study that was part of the Fifth International Survey of Lupus Anticoagulants (ISLA-5). One LA negative plasma containing heparin, six LA positive plasmas and a normal pooled plasma (NP) were distributed to 31 laboratories world-wide together with two APTT reagents, one with a high and one with a low phospholipid concentration. The laboratories performed two APTTs, one with each reagent, on 1:1 mixtures of test plasma and NP. The ratio between the two clotting times was divided by the corresponding ratio for the NP. This final ratio is the LR of that plasma. The overall sensitivity was found to be 95.1%, and the normal, heparin-containing sample was reported to be negative by all the laboratories. When the results were grouped in low, medium and high positive plasmas, a "consensus" regarding the strength of each plasma was easily found. 85.0% of the results were in agreement with this consensus. This study shows that with the LR test, it is possible to obtain high interlaboratory agreement regarding the presence or absence of LA as well as the semi-quantification of this inhibitor.
Collapse
Affiliation(s)
- E M Jacobsen
- Haematological Research Lab., Medical Clinic, Ullevål University Hospital, Oslo, Norway.
| | | | | | | | | |
Collapse
|
21
|
Yamazaki M, Aoshima K, Mizutani T, Ontachi Y, Saito M, Morishita E, Asakura H, Matsuda T, Triplett DA. Prednisolone inhibits endotoxin-induced disseminated intravascular coagulation and improves mortality in rats: importance of inflammatory cytokine suppression. Blood Coagul Fibrinolysis 1999; 10:321-30. [PMID: 10493213 DOI: 10.1097/00001721-199909000-00002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In order to determine whether prednisolone has a protective effect against the development of disseminated intravascular coagulation (DIC), we measured the effect of prednisolone on changes in hemostatic parameters and plasma levels of inflammatory cytokines in endotoxin-treated rats. Decreases in platelet count and fibrinogen levels, prolongation of prothrombin time, and increases in the plasma fibrin degradation products and levels of thrombin-antithrombin III (TAT) complex following the administration of endotoxin, all of which are associated with DIC, were significantly suppressed by the administration of prednisolone. Heparin administration significantly suppressed changes in all these parameters except for the decrease in platelet count. The combination of prednisolone and heparin was more effective than either treatment alone. In order to determine whether these effects of prednisolone are correlated with the suppression of inflammatory cytokine production, we examined the relationship between changes in plasma levels of cytokine, the hemostatic parameters listed above, and mortality using a number of intervention regimens designed to alter events of the experimentally induced DIC. Changes in hemostatic parameters associated with DIC following 30 mg/kg per 4 h of endotoxin infusion were significantly suppressed by treatment with 1 mg/kg prednisolone 30 min before beginning endotoxin infusion, followed by administration of 250 U/kg heparin 2 h after the start of endotoxin infusion (prednisolone-endotoxin-heparin regimen). The heparin and prednisolone were administrated subcutaneously. The administration of prednisolone and heparin in the reverse order (i.e. heparin first and prednisolone second: heparin-endotoxin-prednisolone regimen) also suppressed changes in hemostatic parameters, albeit to a smaller degree. Cytokine production was also significantly suppressed by the first treatment, but was not affected by the regimen in which heparin was administered first. Administration of prednisolone alone or heparin alone 30 min before endotoxin significantly reduced the number of renal glomeruli with fibrin thrombi. Plasma levels of creatinine and alanine transferase were reduced only by prednisolone. Increased plasma levels of interleukin-1beta, tissue necrosis factor-alpha and interleukin-6 were suppressed by prednisolone but not by heparin, and there were significant correlations between plasma levels of TAT and cytokines. Prednisolone was more effective than heparin in reducing mortality at 24 h after 100 mg/kg over 4 h of endotoxin infusion (four of 20 versus 15 of 20 deaths for prednisolone and heparin, respectively). These findings suggest that prednisolone inhibits the development of endotoxin-induced DIC and reduces mortality by a different mechanism than heparin, possibly through suppressing the production of inflammatory cytokines. Prednisolone may be efficacious in preventing DIC and multiple organ dysfunction caused by endotoxin.
Collapse
Affiliation(s)
- M Yamazaki
- Third Department of Internal Medicine, Kanazawa University School of Medicine, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999. [PMID: 10403256 DOI: 10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- W A Wilson
- Louisiana State University Medical Center, New Orleans 70112-2822, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999. [PMID: 10403256 DOI: 10.1002/1529-0131(199907)42] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- W A Wilson
- Louisiana State University Medical Center, New Orleans 70112-2822, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-11. [PMID: 10403256 DOI: 10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f] [Citation(s) in RCA: 1628] [Impact Index Per Article: 65.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- W A Wilson
- Louisiana State University Medical Center, New Orleans 70112-2822, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Dlott JS, Triplett DA. Diagnosing antiphospholipid antibody syndrome. CAP Today 1999; 13:84-8. [PMID: 10350909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Affiliation(s)
- J S Dlott
- Midwest Hemostasis and Thrombosis Laboratories, Muncie, Ind., USA
| | | |
Collapse
|
26
|
Cunningham MT, Praestgaard J, Styer PE, Brandt JT, Fairweather RB, Laposata M, Olson JD, Sosolik RC, Triplett DA. A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys. Arch Pathol Lab Med 1999; 123:199-205. [PMID: 10086507 DOI: 10.5858/1999-123-0199-amfpto] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE To develop a grading scheme for the proficiency testing of small peer groups of fewer than 10 members for the prothrombin time (PT) and activated partial thromboplastin time (APTT). METHODS A modified target value for small peer groups was derived based on the assumption that measurement variability in the PT and APTT is more greatly influenced by variations in reagents than in instruments. Criteria for grading were established by statistical simulation to achieve misclassification errors of less than 5% for both incorrectly passing and failing participants. College of American Pathologists Coagulation Survey data were analyzed to determine the number of additional laboratories graded using the proposed scheme, as well as the failure rates among participants in the small peer groups. RESULTS The modified target value for small peer groups is a weighted average between the mean of the peer group and the mean of all participants using the same reagent (reagent group). Peer groups with as few as 4 members can be graded provided that specific criteria are satisfied: there must be at least 5 peer groups for the same reagent, at least 3 of these 5 peer groups must have more than 3 members, and the coefficient of variation for the reagent group must be less than 10%. This proposed grading scheme decreased the number of ungraded laboratories by 44% to 46% for the PT and 42% to 55% for the APTT. The percentage of failing grades among participants in the small peer groups ranged from 1.3% to 4.1% for the PT and 1.4% to 7.2% for the APTT. These failure rates were 2.8- to 13.0-fold higher than the failure rates in large peer groups (P < or = .05). CONCLUSIONS The proposed small peer group grading scheme can improve the effectiveness of College of American Pathologists proficiency testing for the PT and APTT and may also be generally applicable to other test methods and analytes.
Collapse
Affiliation(s)
- M T Cunningham
- Department of Pathology and Laboratory Medicine, Veterans Affairs Medical Center, Kansas City, MO 64128, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42:167-74. [PMID: 9920027 DOI: 10.1002/1529-0131(199901)42:1<167::aid-anr20>3.0.co;2-b] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To clarify mechanisms of the thrombosis associated with anticardiolipin antibodies (aCL), we examined the effects on activated protein C (APC) of monoclonal aCL and beta2-glycoprotein I (beta2GPI), which is required for formation of the epitopes of aCL. METHODS We developed the chromogenic assay, in which the degradation of coagulation factor Va by APC is reflected in the reduced generation of thrombin from prothrombin, using soybean trypsin inhibitor to inhibit APC. APC activities were measured in the presence and absence of 3.4 microM beta2GPI and/or 2.5 microg/ml of IgM monoclonal aCL (EY2C9 and EY1C8) established from peripheral blood lymphocytes obtained from a patient with aCL. RESULTS Without APC, the formed thrombin activity decreased by the addition of 3.4 microM beta2GPI. When 12.8 nM APC was added, beta2GPI partially reversed the APC-induced inhibition of thrombin generation in a concentration-dependent manner. With 3.4 microM beta2GPI, the thrombin generation in monoclonal aCL (2.5 microg/ml) decreased to 77.1-80.2% by the addition of 12.8 nM APC, but the values were above that in the control IgM (72.7%). Without beta2GPI, the APC activity was unaffected by the addition of monoclonal aCL. CONCLUSION Beta2-glycoprotein I exhibits procoagulant activity by inhibiting APC activity and anticoagulant activity by inhibiting thrombin generation. Any further inhibition of APC activity was caused by monoclonal aCL and only in the presence of beta2GPI.
Collapse
Affiliation(s)
- M Ieko
- Department of Internal Medicine, School of Dentistry, Health Science University of Hokkaido, Ishikari-Toubetsu, Japan
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Lupus anticoagulants (LA) are immunoglobulins which inhibit one or more of the in-vitro phospholipid (PL) dependent tests of coagulation. Virtually any physician may encounter LA-positive patients. Such patients present with a variety of diagnostic challenges including arterial and venous thromboembolic events, recurrent fetal loss, TIAs, livedo reticularis, etc. LA and anticardiolipin antibodies (ACA) are the most common cause of acquired thrombophilia. Consequently, it is imperative for clinicians and laboratorians to work together in establishing the diagnosis of LA/ACA. The laboratory diagnosis of LA requires careful adherence to the SSC Subcommittee on Lupus Anticoagulants/Phospholipid-dependent Antibodies guidelines. Four sequential steps are required, including: screening tests, mixing studies (to establish the presence of an inhibitor), confirmatory tests based on increased or altered PL concentrations, and ruling out other coagulopathies (for example, factor VIII inhibitor).
Collapse
Affiliation(s)
- D A Triplett
- Midwest Hemostasis and Thrombosis Laboratories, USA.
| |
Collapse
|
29
|
|
30
|
Fairweather RB, Ansell J, van den Besselaar AM, Brandt JT, Bussey HI, Poller L, Triplett DA, White RH. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med 1998; 122:768-81. [PMID: 9740135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVE To review the state of the art of laboratory monitoring of oral anticoagulant therapy, as reflected by the medical literature and the consensus opinion of recognized experts in the field, and to make recommendations for improvement in laboratory monitoring of oral anticoagulant therapy. DATA SOURCES Review of the medical literature, primarily from the last 10 years, and current laboratory practices by a panel of 8 international experts in the field of oral anticoagulant monitoring. DATA EXTRACTION AND SYNTHESIS After an initial assessment of the literature, key points were identified. Experts were assigned to do an in-depth review of the literature and current practices relevant to each of the key points and to prepare a summary of their findings and recommendations. A draft manuscript was prepared and circulated to every participant in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. Each of the key points and associated recommendations was then presented for discussion at the Conference. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form. CONCLUSIONS Consensus was reached on 12 recommendations concerning the laboratory monitoring of oral anticoagulant therapy. Detailed discussion of the rationale for each of these recommendations is found in the text of this article. Discussion of points on which consensus was not reached is also included in the text. It is hoped that widespread adoption of these recommendations will further improve the laboratory monitoring of oral anticoagulant therapy.
Collapse
Affiliation(s)
- R B Fairweather
- Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Yamazaki M, Asakura H, Saito M, Jokaji H, Uotani C, Kumabashiri I, Morishita E, Aoshima K, Matsuda T, Triplett DA. Prothrombin fragment 1 + 2 measures treatment effect in patients with antiphospholipid syndrome. Thromb Res 1998; 91:121-8. [PMID: 9733155 DOI: 10.1016/s0049-3848(98)00074-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis. The anticoagulant management of APS thrombosis remains controversial. Few reports on markers of in vivo activation of coagulation have been reported. To determine whether plasma levels of prothrombin fragment 1 + 2 (F1 +2) correlate with thrombotic risk and treatment effect in patients with APS, plasma F1 + 2 levels were followed in 57 patients with this syndrome for more than 2 years. Clinical findings were also observed in these patients. Plasma levels of F1 + 2 in patients with APS were significantly higher when compared with control subjects (p<.05). These results suggest patients with APS are in a hypercoagulable state. Plasma levels of F1 + 2 significantly decreased following treatment with either aspirin, or aspirin plus warfarin (p<.05 and p<.01, respectively). Recurrent thromboses or spontaneous abortions occurred in all eight patients whose plasma levels of F1 + 2 remained higher than 1 nmol/l after treatment with either aspirin alone or no anticoagulants. These patients were subsequently treated with warfarin as well as aspirin, and plasma levels of F1 + 2 decreased to less than 1 nmol/l, with no additional thrombotic events over the remainder of the 2-year follow-up. No fatal bleeding was observed in treated patients. Our results suggest plasma levels of F1 + 2 are useful indicators of successful treatment. It is also suggested that warfarin plus mini-dose aspirin therapy is effective for patients with APS to protect from recurrent thromboses without harmful side effects. Further, prospective cohort studies are needed to substantiate these associations.
Collapse
Affiliation(s)
- M Yamazaki
- Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
With the aging population, the use of warfarin will continue to increase. The introduction of new thromboplastins with International Sensitivity Indices (ISI) of 1.0 to 1.5 has improved the efficacy of monitoring warfarin therapy with the prothrombin time (PT). Increasingly, outpatient oral anticoagulant clinics and home testing are the sites for PT monitoring.
Collapse
Affiliation(s)
- D A Triplett
- Department of Pathology, Indiana University School of Medicine, USA
| |
Collapse
|
33
|
Peterson P, Hayes TE, Arkin CF, Bovill EG, Fairweather RB, Rock WA, Triplett DA, Brandt JT. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998; 133:134-9. [PMID: 9484723 DOI: 10.1001/archsurg.133.2.134] [Citation(s) in RCA: 179] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The major conclusions of this position article are as follows: (1) In the absence of a history of a bleeding disorder, the bleeding time is not a useful predictor of the risk of hemorrhage associated with surgical procedures. (2) A normal bleeding time does not exclude the possibility of excessive hemorrhage associated with invasive procedures. (3) The bleeding time cannot be used to reliably identify patients who may have recently ingested aspirin or nonsteroidal anti-inflammatory agents or those who have a platelet defect attributable to these drugs. The best preoperative screen to predict bleeding continues to be a carefully conducted clinical history that includes family and previous dental, obstetric, surgical, traumatic injury, transfusion, and drug histories. A history suggesting a possible bleeding disorder may require further evaluation; such an evaluation may include performance of the bleeding time test, as well as a determination of the platelet count, the prothrombin time, and the activated partial thromboplastin time. In the absence of a history of excessive bleeding, the bleeding time fails as a screening test and is, therefore, not indicated as a routine preoperative test.
Collapse
Affiliation(s)
- P Peterson
- Department of Pathology, Cornell University Medical College, New York, NY, USA
| | | | | | | | | | | | | | | |
Collapse
|
34
|
|
35
|
Triplett DA. Lupus anticoagulants: diagnostic dilemma and clinical challenge. Clin Lab Sci 1997; 10:223-8. [PMID: 10169622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Lupus anticoagulants (LAs) are immunoglobulins which prolong 1 or more of the in vitro phospholipid-dependent tests of coagulation (e.g., activated partial thromboplastin time [APTT], dilute Russell viper venom time [dRVVT], kaolin clotting time [KCT], and textarin time [TT]). Paradoxically, patients with LAs rarely experience hemorrhagic problems. Approximately 1/3 of individuals with LAs experience thromboembolic complications such as stroke, deep vein thrombosis, and pulmonary emboli. LAs are members of the antiphospholipid antibody (APA) family. The APA family includes: LAs, anticardiolipin antibodies (ACAs), and reagin (the antibody responsible for the positive serologic test for syphilis). In approximately 60% of the patients, a LA and an ACA will both be present. The diagnosis of LAs requires an organized approach. Careful preparation of platelet poor plasma (PPP) is essential to assure maximum detection of LA. In order to rule out LAs, it is necessary to perform at least 2 screening tests (e.g., APTT, dRVVT). Additional steps in the diagnosis of LAs include mixing studies to identify the presence of an inhibitor and confirmatory procedures to demonstrate phospholipid-dependence of the inhibitor. It is also important to rule out any other potential coagulopathies which may account for the prolonged screening studies.
Collapse
Affiliation(s)
- D A Triplett
- Midwest Hemostasis and Thrombosis Laboratories, Muncie, IN 47303, USA
| |
Collapse
|
36
|
Ieko M, Triplett DA, Kohno M, Ohmoto A, Notoya A, Sawada K, Koike T. [A study on antiprothrombin antibodies in antiphospholipid syndrome]. Rinsho Ketsueki 1997; 38:426-32. [PMID: 9194388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In this study we investigated the frequency and the type of manifestations of antiprothrombin antibodies (aFII) in patients with antiphospholipid syndrome (APS). In 16 (84.2%) of 19 patients with lupus anticoagulant (LA) and either anticardiolipin antibodies or antiphosphatidylserine antibodies, two types of abnormal patterns were shown on a crossed immuno-electrophoresis technique using anti-human prothrombin murine IgG. The slow-moving peak of prothrombin was detected in 8 patients, while a peak in the other patients had the slow-moving shoulder. These slow-moving materials might represent prothrombin-aFII complexes. In 13 patients who were studied on Western blots, IgGs of 11 patients (84. 6%) bound to human purified prothrombin, and the IgGs of 7 (53.8%) of these patients also bound to human purified alpha-thrombin. Our results indicate that aFII detected in patients with APS may explain part of the mechanism of LA.
Collapse
Affiliation(s)
- M Ieko
- Department of Clinical Immunology and Hematology, Sapporo City General Hospital, Japan
| | | | | | | | | | | | | |
Collapse
|
37
|
Triplett DA. Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment). Haemostasis 1996; 26 Suppl 4:358-67. [PMID: 8979140 DOI: 10.1159/000217317] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Antiphospholipid-protein antibodies (APA) are a family of immunoglobulins which recognize protein-phospholipid complexes. Among the proteins implicated are: beta 2 Glycoprotein I, prothrombin, Annexin V, protein C, and protein S. Laboratory tests are used to identify, predict potential clinical complications, and manage patients with the antiphospholipid-protein syndrome (APS). Emerging evidence suggests laboratory tests can be used to stratify relative risk of patients with APA.
Collapse
Affiliation(s)
- D A Triplett
- Ball Memorial Hospital, Muncie, Indiana 47303, USA
| |
Collapse
|
38
|
Abstract
Antiphospholipid-protein antibodies (APA) represent a family of immunoglobulins which recognize protein-phospholipid complexes. A variety of proteins have been implicated including: prothrombin, annexin V, beta 2-Glycoprotein I, and protein S. APA are detected utilizing either coagulation-based tests to identify lupus anticoagulants (LA) or solid phase ELISA assays to identify anticardiolipin antibodies (ACA). APA may be seen in a variety of different clinical settings including convalescence from infections, resulting from exposure to certain drugs, or in association with autoimmune diseases. Autoimmune APA have been linked to a variety of thromboembolic complications involving both arterial and venous sites. In addition, recurrent fetal loss has been linked to a APA. The underlying pathophysiology of the thromboembolic events remains controversial. Given the diversity of anatomic sites, more than one thromboembolic mechanism(s) is likely. Abnormalities of the protein C system most likely account for the venous thromboembolic events. Because of the spectrum of clinical complications, virtually any clinician may encounter patients with the APA syndrome (thrombosis, thrombocytopenia, recurrent fetal loss coupled with positive LA or ACA testing).
Collapse
Affiliation(s)
- D A Triplett
- Indiana University School of Medicine, Muncie, USA
| |
Collapse
|
39
|
Triplett DA. Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid-protein antibodies. Ann Med Interne (Paris) 1996; 147 Suppl 1:5-9. [PMID: 8952751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The diagnosis of antiphospholipid-protein antibodies and the related clinical complications requires an integrated approach with a carefully planned sequential evaluation of the patient and appropriate laboratory testing. Optimal patient diagnosis and management necessitates cooperative planning involving the clinician and laboratory staff.
Collapse
|
40
|
Abstract
Protein C is a major regulatory protein critical to physiologic anticoagulation. When activated, it selectively degrades the activated forms of factors V and VIII, thereby, down-regulating blood coagulation. Using an activated partial thromboplastin time (APTT) assay, Dahlback et al. recently reported that some individuals with thrombophilia show a poor in vitro anticoagulant response to activated protein C (APC-Resistance). Subsequent studies identified a point mutation in the gene for factor V as the underlying cause of APC-Resistance. The incidence of APC-Resistance in patients with recurrent thromboembolic events approaches 50%. The APC-Resistance phenotype is also present in approximately 5% of normal Caucasian subjects. In an attempt to develop a more sensitive and specific test system, we evaluated an assay based on Textarin(Pentapharm, Basel, Switzerland). Textarin, a protein fraction of Pseudonaja textilis venom (Australian Eastern Brown Snake) activates prothrombin in the presence of phospholipid (PL), factor V and calcium ions. Based on Textarin's requirement for factor V, we developed a Textarin time assay to test for APC-Resistance. We evaluated this test system in normal subjects and the following patient populations: stable orally anticoagulated, previously diagnosed factor V Leiden, and therapeutically heparinized samples. We found the Textarin assay to be a sensitive and specific test system to identify APC-Resistance. The phenotypic Textarin APC-Resistance test correlated more closely with the genotypic abnormality of factor VR506Q than the APTT-APC-Resistance test.
Collapse
Affiliation(s)
- L E Hoagland
- Muncie Center for Medical Education, Indiana University School of Medicine, USA
| | | | | | | |
Collapse
|
41
|
|
42
|
Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA, Koike T. Human beta2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87:3262-70. [PMID: 8605342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
beta2-Glycoprotein I (beta2-GPI) consists of five repeats of a homologous domain. We designed a series of human beta2-GPI mutant genes, ie, three mutant genes lacking the domain(s) present in the NH2-terminal region and two of those present in the COOH-terminal region. These mutant genes were expressed in Spodoptera frugiperda insect cells (Sf9) infected with recombinant baculoviruses and the mutant proteins were secreted into the culture medium. The molecular mass of the purified mutant proteins, estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was fairly consistent with the size calculated from their nucleotide sequences. Binding of beta2-GPI to solid-phase cardiolipin (CL) was diminished by the deletion of the fifth domain (domain V) from its complete structure. Thus, the phospholipid binding site of beta2-GPI is located on its domain V. Monoclonal anti-CL antibodies (aCL) derived either from NZW x BXSB (WB) F1 mice or from patients with antiphospholipid syndrome bound directly to the domain V-deleted mutant protein (DI-IV) absorbed not only on an oxygenated but also on a plain polystyrene surface. We conclude from this study that the epitope for aCL is exposed on a conformationally changed structure of beta2-GPI by interacting with negatively charged phospholipid or on the mutant protein, DI-IV.
Collapse
Affiliation(s)
- M Igarashi
- Microbiology Laboratory, Yamasa Corp, Choshi, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74:1597-603. [PMID: 8772243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Lupus anticoagulants (LAs) are antibodies that interfere with phospholipid dependent coagulation reactions in vitro. This workshop was designed to provide the participants with an experience in identification of LAs, to evaluate different criteria for mixing studies, to assess the performance of recently introduced confirmatory studies and to assess the performance of two potential surrogate LA control plasmas. The results demonstrate that there continues to be significant variation in the sensitivity and responsiveness of APTT reagents to the presence of LAs, confirming the need for more than one screening assay before the presence of a LA can be ruled out. In this workshop, the best distinction between factor deficiency and inhibitors was obtained using a 1:1 mix of normal plasma with patient plasma and the criterion defining correction as shortening of the APTT to within 5 s of the APTT of pooled normal plasma. A 4:1 mix of patient to normal plasma did not work well in distinguishing factor deficiency from inhibitors. The platelet neutralization procedure, DVV confirm and StaClot LA all gave positive results with the LA samples. False positive platelet neutralization procedures were seen with the samples from patients on oral anticoagulants and a factor V inhibitor. False positive StaClot LA results were obtained with high titer factor VIII inhibitors. Both of the potential surrogate plasmas gave variable results with multiple assays; they can not be recommended for routine use at present.
Collapse
Affiliation(s)
- J T Brandt
- Department of Pathology, Ohio State University, Columbus 43210, USA
| | | | | |
Collapse
|
44
|
Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-90. [PMID: 8560433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- J T Brandt
- Dep. of Pathology, Ohio State University, Columbus 43210, USA
| | | | | | | |
Collapse
|
45
|
Triplett DA. Protean clinical presentation of antiphospholipid-protein antibodies (APA). Thromb Haemost 1995; 74:329-37. [PMID: 8578480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Antiphospholipid-protein antibodies (APA) are a family of immunoglobulins which have been defined by varying laboratory test systems. Lupus anticoagulants (LA) and anticardiolipin antibodies (ACA) are the two most prominent members of this family of antibodies. LA are detected utilizing various phospholipid (PL) dependent tests of coagulation (e.g., activated partial thromboplastin time [APTT], Kaolin Clotting Time [KCT], dilute Russell Viper Venom Time [dRVVT]). Originally, LA were thought to be a laboratory nuisance since the vast majority of individuals with LA did not bleed. Paradoxically, patients with LA were found to have an increased incidence of thromboembolic events and also recurrent spontaneous abortions (RSA). Thus, the laboratory detection of LA has become part of the work up of patients with thromboembolic disorders and RSA. ACA are detected using solid phase assay systems (radioimmunoassay or ELISA). The presence of ACA has the same clinical implications as that of LA. Although originally it was suggested ACA and LA were the same antibody, it is now well accepted that they, in many instances, are different antibodies. Therefore, it is critical for laboratories to evaluate patient samples for both LA and ACA. In approximately 60% of circumstances, both antibodies will be found. In the remaining cases, there will be discordance between the two test systems. The question of whether APA are causative, coincidental, or a consequence of the clinical complications of RSA and thrombosis remains controversial. Recent evidence based on prospective clinical studies and analysis of markers of in vivo coagulation suggests APA are causative.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- D A Triplett
- School of Medicine, Indiana University, Muncie, USA
| |
Collapse
|
46
|
Affiliation(s)
- D A Triplett
- Indiana University School of Medicine, Ball Memorial Hospital, Muncie 47303-3499, USA
| |
Collapse
|
47
|
Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K. A comparison of lyophilized artificially depleted plasmas and lyophilized plasmas from patients receiving warfarin in correcting for coagulometer effects on international normalized ratios. Am J Clin Pathol 1995; 103:366-71. [PMID: 7872262 DOI: 10.1093/ajcp/103.3.366] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
The comparative value of lyophilized artificially depleted plasmas and plasmas from warfarin-treated patients in local (thromboplastin/coagulometer) system International Sensitivity Indices (ISI) determination has been studied at 39 centers in an international collaborative study. At each center, both types of plasmas were tested with two common thromboplastins (low ISI RecombiPlasTin and high ISI OBT), and in-house reagents using three brands of coagulometers. In 95 local systems, they was agreement. With both thromboplastins, coagulometers lowered the ISI from the manual or stated ISI with all systems. Differences between the two types of lyophilized plasmas with the two common thromboplastins were not of clinical importance. Artificially depleted plasmas are easier to obtain in sufficient volumes than plasma from warfarin-treated patients, and more easily provide the wide range of INR values required for reliable local ISI calibration. The agreement between the two types of lyophilized calibrant is reassuring.
Collapse
Affiliation(s)
- L Poller
- Department of Pathological Sciences, Medical School, University of Manchester, UK
| | | | | | | | | |
Collapse
|
48
|
Triplett DA. Antiphospholipid antibodies, lupus anticoagulants and thromboembolic disease. Haematologica 1995; 80:122-6. [PMID: 7628764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Affiliation(s)
- D A Triplett
- Indiana University School of Medicine, Ball Memorial Hospital, Muncie, USA
| |
Collapse
|
49
|
Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K. The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study. Am J Clin Pathol 1995; 103:358-65. [PMID: 7872261 DOI: 10.1093/ajcp/103.3.358] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
A study of lyophilized plasma calibrants in correcting for coagulometer effects on International Normalized Ratios (INR) has been conducted in an international survey. Prothrombin times were performed with the calibrants on 2 "common" thromboplastins and in-house thromboplastins in 3 brands of coagulometer at 37 centers. The International Sensitivity Indices (ISI) of 95 local systems with the calibrants were derived. The "true" INR of 10 test plasmas from warfarin-treated patients were established centrally using thromboplastin International Reference Preparations (IRP). International Normalized Ratios of these plasmas for each center were calculated using both the manufacturers' stated and the local ISI. The mean deviation of the 95 systems from the "true" INR of the warfarin plasmas was +14.4% with the manufacturers' ISI, but reduced to +1.04% with the local ISI. Local ISI determination with the calibrants avoids many of the difficulties of conventional thromboplastin calibrations. Plasmas from patients on warfarin and parallel manual PT with thromboplastin IRP are not required.
Collapse
Affiliation(s)
- L Poller
- Department of Pathological Sciences, Medical School, University of Manchester, UK
| | | | | | | | | |
Collapse
|
50
|
Matsuura E, Igarashi M, Igarashi Y, Katahira T, Nagae H, Ichikawa K, Triplett DA, Koike T. Molecular studies on phospholipid-binding sites and cryptic epitopes appearing on beta 2-glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 1995; 4 Suppl 1:S13-7. [PMID: 7538850 DOI: 10.1177/096120339400400104] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- E Matsuura
- Immunology Laboratory, Yamasa Corporation, Choshi, Japan
| | | | | | | | | | | | | | | |
Collapse
|